10.24.2023 - By PeerVoice
Visit https://www.peervoice.com/AJD860 to view the entire programme with slides. After completing “Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma”, participants will be able to: Evaluate evolving data and evidence impacting the treatment landscape in advanced cholangiocarcinoma (CCA); Recognise opportunities to optimise molecular testing pathways in CCA through multidisciplinary team engagement; Identify patient-, disease-, and drug-specific considerations which guide treatment planning in advanced CCA; and Design personalised treatment regimens for patients with CCA taking into account safety, efficacy, and overall outcomes.